Zegbeh Jallah
Stock Analyst at Capital One
(2.97)
# 1,217
Out of 4,829 analysts
25
Total ratings
34.78%
Success rate
111.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $1.53 | +6,435.95% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.24 | +4,895.84% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $5.81 | +657.31% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $3.77 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $17.42 | +66.48% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $0.75 | +6,270.27% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $5.27 | +1,228.27% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $3.70 | +467.57% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $6.61 | +1,942.36% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.91 | +4,436.08% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.67 | +795.52% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $11.90 | +362.38% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.62 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.86 | +831.53% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $600 | $3.37 | +17,704.15% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $1.53
Upside: +6,435.95%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.24
Upside: +4,895.84%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $5.81
Upside: +657.31%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $3.77
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $17.42
Upside: +66.48%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $0.75
Upside: +6,270.27%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $5.27
Upside: +1,228.27%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $3.70
Upside: +467.57%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $6.61
Upside: +1,942.36%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.91
Upside: +4,436.08%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.67
Upside: +795.52%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $11.90
Upside: +362.38%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $3.62
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.86
Upside: +831.53%
Dec 18, 2019
Initiates: Buy
Price Target: $600
Current: $3.37
Upside: +17,704.15%